This article was originally published in The Gray Sheet
Executive SummaryCompletes $12.5 mil. private placement of 4% convertible preferred stock. The funds strengthen the imaging and therapeutic product maker's financial position as it continues to boost marketing efforts for CEA-Scan (arcitumomab) in the U.S. and Europe, and for LeukoScan (sulesomab) in Europe. Plans for U.S. marketing of LeukoScan, pending FDA approval, are also under way. Subject to certain conditions, the firm has an option for up to an additional $7.5 mil. convertible preferred stock offering
You may also be interested in...
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.